Divi’s Laboratories Surpasses Expectations with 45% Profit Jump in Q2

Divi’s Laboratories reported a strong 45% rise in profit and EBITDA for Q2, exceeding market expectations. The growth was driven by strong demand for its pharmaceutical products and improved operational efficiency. The company’s revenue also saw a significant boost, reinforcing its strong position in the API market. Divi’s continues to benefit from its robust product portfolio and global presence, positioning it well for future growth.